AMYPAD Diagnostic and Patient Management Study: Rationale and design

Frisoni, Giovanni; Barkhof, Frederik; Canzoneri, Elisa

doi:10.1016/j.jalz.2018.09.003

Scientific article

English

AMYPAD Diagnostic and Patient Management Study: Rationale and design

ContributorsFrisoni, Giovanni; Barkhof, Frederik; Canzoneri, Elisa

CollaboratorsAltomare, Daniele; Boccardi, Marina; Garibotto, Valentina

Published inAlzheimer's & Dementia

Publication date2018

Abstract

Reimbursement of amyloid-PET is lagging due to the lack of definitive evidence on its clinical utility and cost-effectiveness. The Amyloid Imaging to Prevent Alzheimer's Disease-Diagnostic and Patient Management Study (AMYPAD-DPMS) is designed to fill this gap.

Keywords

Amyloid-PET
Alzheimer's disease
Mild cognitive impairment
Subjective cognitive decline
Clinical validity
Cost-effectiveness

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de réadaptation et gériatrie

Research groups

Citation (ISO format)

FRISONI, Giovanni, BARKHOF, Frederik, CANZONERI, Elisa. AMYPAD Diagnostic and Patient Management Study: Rationale and design. In: Alzheimer’s & Dementia, 2018. doi: 10.1016/j.jalz.2018.09.003

Article (Published version)

CC BY-NC-ND

Identifiers

PID : unige:114054
DOI : 10.1016/j.jalz.2018.09.003
PMID : 30339801

ISSN of the journal1552-5260

388views

264downloads

Creation04/01/2019 16:41:00

First validation04/01/2019 16:41:00

Update time15/03/2023 15:43:08

Status update15/03/2023 15:43:08

Last indexation16/10/2024 19:28:42

Archive ouverte UNIGE

AMYPAD Diagnostic and Patient Management Study: Rationale and design

Reimbursement of amyloid-PET is lagging due to the lack of definitive evidence on its clinical utility and cost-effectiveness. The Amyloid Imaging to Prevent Alzheimer's Disease-Diagnostic and Patient Management Study (AMYPAD-DPMS) is designed to fill this gap.

Technical informations